Sanofi and Exscientia to Develop Bispecific Molecules for Diabetes
By Jasmine Kalsi
Pharma Deals Review: Vol 2017 Issue 5 (Table of Contents)
Published: 25 May-2017
DOI: 10.3833/pdr.v2017.i5.2247 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Searching for new avenues to differentiate its diabetes offerings, Sanofi has entered into an alliance with artificial intelligence (AI) specialist, Exscientia, to develop bispecific small molecules...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS